Back to Search
Start Over
Controversies in Optimal Anemia Management : Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
- Source :
- unknow, unknow, 2021, unknow, France. pp.1280-1295, ⟨10.1016/j.kint.2021.03.020⟩, Kidney international, Vol. 99, no. 6, p. 1280-1295 (2021)
- Publication Year :
- 2021
- Publisher :
- Uppsala universitet, Institutionen för medicinsk cellbiologi, 2021.
-
Abstract
- International audience; In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis, evaluation, and treatment of anemia in chronic kidney disease. Since then, new data have accrued from basic research, epidemiological studies, and randomized trials that warrant a re-examination of previous recommendations. Therefore, in 2019, KDIGO decided to convene 2 Controversies Conferences to review the latest evidence, explore new and ongoing controversies, assess change implications for the current KDIGO anemia guideline, and propose a research agenda. The first conference, described here, focused mainly on iron-related issues, including the contribution of disordered iron homeostasis to the anemia of chronic kidney disease, diagnostic challenges, available and emerging iron therapies, treatment targets, and patient outcomes. The second conference will discuss issues more specifically related to erythropoiesis-stimulating agents, including epoetins, and hypoxia-inducible factor-prolyl hydroxylase inhibitors. Here we provide a concise overview of the consensus points and controversies resulting from the first conference and prioritize key questions that need to be answered by future research.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
dialysi
Anemia
medicine.medical_treatment
[SDV]Life Sciences [q-bio]
030232 urology & nephrology
law.invention
03 medical and health sciences
0302 clinical medicine
Prolyl-Hydroxylase Inhibitor
iron
iron deficiency
Randomized controlled trial
Hematinic
law
Basic research
erythropoiesis stimulating agent
Epidemiology
Urologi och njurmedicin
medicine
Humans
Urology and Nephrology
Renal Insufficiency, Chronic
Intensive care medicine
Dialysis
business.industry
Prolyl-Hydroxylase Inhibitors
Guideline
medicine.disease
Anemia management
anemia
3. Good health
erythropoiesis stimulating agents
030104 developmental biology
Nephrology
Hematinics
dialysis
erythropoietin
hepcidin
hypoxia-inducible factor-prolyl hydroxylase inhibitor
business
chronic kidney disease
Kidney disease
Human
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- unknow, unknow, 2021, unknow, France. pp.1280-1295, ⟨10.1016/j.kint.2021.03.020⟩, Kidney international, Vol. 99, no. 6, p. 1280-1295 (2021)
- Accession number :
- edsair.doi.dedup.....0ae22d3a3f503a2688178ee0cd2c9547